Physician profile
Patrick J Glynn
NPI 1508050857
$21,636.49
in general payments reported to CMS, 2019-2025
76 companies · $3,734 in 2025
The $3,734 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,712 · 2020: $2,487 · 2021: $3,237 · 2022: $2,921 · 2023: $3,213 · 2024: $3,333 · 2025: $3,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,262.40 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $2,208.06 | 2019-2025 | Nuplazid |
| Abbvie INC. | $1,634.19 | 2021-2025 | |
| Ucb, INC. | $1,108.96 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Biogen, INC. | $1,000.67 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Amgen INC. | $941.40 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $924.05 | 2019-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $889.96 | 2019-2025 | |
| Pfizer INC. | $875.38 | 2019-2025 | |
| Lilly USA, LLC | $791.39 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $701.86 | 2019-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $627.42 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $530.37 | 2019-2025 | |
| Horizon Therapeutics Plc | $526.80 | 2021-2023 | Uplizna |
| Csl Behring | $484.08 | 2019-2024 | Hizentra |
| Genzyme Corporation | $444.04 | 2019-2025 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Glynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.